Accro Bioscience
Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease.
$50MSeries C
Role not disclosedL
LAV
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $265.2M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedExcalipoint Therapeutics
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
$27.7MSeed+
Role not disclosedCaldera Therapeutics
Develops bispecific antibody CLD-423 for inflammatory bowel disease
$37.5MSeries A1
Role not disclosed